Last updated: September 24, 2026
Extended phenytoin sodium is a mature, genericized antiseizure medicine with limited patent protection and low standalone revenue visibility. The market is driven by chronic maintenance use, hospital-to-outpatient continuity, low unit prices, therapeutic drug monitoring, and supply reliability rather than by new clinical differentiation. Dilantin Kapseals remains the reference product, while generic phenytoin sodium extended-release capsules supply most volume.
What is the current market position of extended phenytoin sodium?
Extended phenytoin sodium is primarily sold as an oral extended-release capsule for maintenance treatment of generalized tonic-clonic and complex partial seizures. The reference product is Dilantin Kapseals, marketed by Viatris under its legacy Upjohn portfolio after Pfizer’s Upjohn business combination with Mylan. Generic versions are available from multiple manufacturers.
The product has three defining commercial characteristics:
| Market characteristic |
Effect |
| Mature generic product |
Limits pricing power and new-product upside |
| Narrow therapeutic index |
Supports continued prescribing but complicates substitution and switching |
| Extended-release formulation |
Creates manufacturing and bioequivalence requirements that are more demanding than a simple immediate-release tablet |
Phenytoin is still used in epilepsy care, but newer antiseizure medicines have reduced its role in many treatment pathways. Clinicians increasingly favor agents such as levetiracetam, lamotrigine, and valproate when clinical circumstances permit. Phenytoin remains relevant in established patients, emergency care, post-traumatic seizure management, and settings where cost and institutional familiarity influence treatment selection.
How large is the extended phenytoin sodium market?
No major manufacturer publicly reports standalone global revenue for extended phenytoin sodium. Public company filings typically combine the product with broader mature medicines, legacy products, or regional portfolios. Prescription-volume and sales estimates also vary depending on whether they include immediate-release phenytoin, injectable fosphenytoin, hospital use, and international formulations.
The addressable market is best characterized as a low-value, high-volume generic segment:
- The reference brand has limited pricing leverage.
- Generic capsules account for most prescriptions.
- Total market value is substantially lower than the value of newer branded antiseizure therapies.
- Revenue is distributed across manufacturers, wholesalers, hospitals, retail pharmacies, and public payers.
- Product demand is relatively stable but structurally exposed to substitution by newer antiseizure drugs.
The commercial opportunity is therefore more attractive for dependable supply and portfolio efficiency than for premium pricing or rapid growth.
What is the financial trajectory for extended phenytoin sodium?
The expected financial trajectory is mature to declining in nominal terms, with periodic price volatility caused by supplier exits, shortages, or changes in generic competition.
Revenue trajectory
Extended phenytoin sodium revenue is likely to follow four phases:
| Period |
Financial pattern |
Primary driver |
| Brand-growth period |
Higher pricing and product differentiation |
Dilantin franchise expansion |
| Generic-entry period |
Sharp price compression |
ANDA competition |
| Mature generic period |
Low, stable revenue |
Chronic maintenance demand |
| Late-maturity period |
Flat to declining base revenue |
Clinical substitution and portfolio rationalization |
Generic entry removed the principal source of pharmaceutical margin. The remaining revenue pool depends on prescription retention, manufacturing cost, wholesaler contracts, and reimbursement terms.
A manufacturer with a low-cost, reliable supply chain can maintain acceptable contribution margins even at low prices. A manufacturer with a small production scale, high quality costs, or unstable active pharmaceutical ingredient supply may leave the market despite continuing clinical demand.
Profitability
Gross margins are generally constrained by:
- Low generic selling prices.
- Pharmacy benefit manager and wholesaler purchasing pressure.
- Regulatory costs associated with a narrow-therapeutic-index product.
- Inventory and testing requirements for extended-release capsules.
- Potential price increases during supply disruption, followed by competitive normalization.
Profitability can improve temporarily when one or more competitors experience manufacturing problems. Those gains are not durable if additional suppliers re-enter or increase production.
When did extended phenytoin sodium lose exclusivity?
The principal product and formulation protections for phenytoin sodium extended-release capsules expired many years ago. The market has no meaningful remaining regulatory exclusivity comparable to the exclusivity periods attached to recently approved small-molecule medicines.
The core exclusivity timeline is:
| Event |
Commercial consequence |
| Original Dilantin approval |
Established the reference product |
| Generic approval of phenytoin sodium extended-release capsules |
Created price competition |
| Expiration of historical formulation and product protections |
Removed durable brand barriers |
| Mature ANDA market |
Shifted competition to price, quality, and supply |
Current commercial protection does not come from a live core patent estate. Any remaining intellectual-property position would more likely involve manufacturing know-how, packaging, device-related elements, or product-specific regulatory records than broad protection over the active ingredient.
What is the Orange Book status of extended phenytoin sodium?
The FDA Orange Book identifies approved drug products and their therapeutic-equivalence information. Extended-release phenytoin sodium capsules are represented through the reference NDA and approved generic ANDAs. The central commercial point is that the product is a mature multisource drug with no important active Orange Book patent barrier generally understood to block generic competition.
For a product-specific diligence review, the relevant Orange Book fields are:
- Reference-listed drug status.
- NDA and ANDA numbers.
- Dosage form and strength.
- Therapeutic-equivalence code.
- Active patent listings, if any.
- Exclusivity codes, if any.
- Marketing status and approval holder.
Orange Book status should be checked by strength and dosage form because extended-release capsules, chewable tablets, oral suspension, and injectable phenytoin products are separate regulatory listings.[1]
Which companies compete in extended phenytoin sodium?
Competition includes the legacy reference product and generic manufacturers that have obtained FDA approval for phenytoin sodium extended-release capsules. Manufacturers and distributors can change over time as companies discontinue low-volume products or transfer approvals.
The principal competitive groups are:
Reference product
Dilantin Kapseals is the branded extended-release capsule associated with the original Dilantin franchise. Brand demand persists among patients and prescribers who prefer continuity, but reimbursement generally favors lower-cost generic alternatives.
Generic manufacturers
Generic supply has historically included large and midsize companies active in solid oral dosage forms. The competitive set can include manufacturers such as Hikma, Taro, Amneal, and other ANDA holders, subject to current marketing status and product availability. A company may retain an approved ANDA while marketing intermittently or not at all.
Contract and supply-chain participants
The economic market also includes:
- Active pharmaceutical ingredient suppliers.
- Capsule and excipient suppliers.
- Contract manufacturing organizations.
- Wholesalers.
- Hospital group purchasing organizations.
- Retail pharmacy networks.
- State and federal payers.
The number of approved ANDAs is less important than the number of manufacturers actively shipping commercial product. A nominally broad approval base can still produce a concentrated effective supply base.
What patent protection covers extended phenytoin sodium?
The active ingredient phenytoin and the sodium salt are long off-patent. The basic extended-release capsule concept is also mature. The practical protection landscape is therefore weak for broad composition claims and limited for new commercial entrants.
Potentially relevant intellectual-property categories include:
| IP category |
Current commercial significance |
| Active ingredient claims |
None of practical significance |
| Salt or basic formulation claims |
Historical or expired |
| Extended-release formulation claims |
Generally expired or commercially weak |
| Manufacturing process claims |
Potentially relevant to cost and quality, but not a broad market barrier |
| Packaging and stability know-how |
Operational value rather than exclusionary value |
| Brand trademarks |
Relevant to Dilantin branding, not generic market access |
| Labeling and regulatory records |
Regulatory value, not patent exclusivity |
The strongest barriers are operational. They include validated manufacturing processes, consistent dissolution performance, control of impurities, stability data, and reliable API sourcing.
Are there Paragraph IV challenges to extended phenytoin sodium?
Paragraph IV litigation is not a significant current market driver for extended phenytoin sodium because the product’s principal patent and exclusivity period ended long ago. A new ANDA applicant would not normally face the same patent-risk profile associated with a recently launched branded medicine.
Historical patent challenges may have occurred during the original generic-entry period, but those disputes have little bearing on current market access. Current entrants are more likely to encounter:
- FDA quality requirements.
- Bioequivalence and dissolution requirements.
- Manufacturing-site inspections.
- Supply-chain qualification.
- Commercial contracting barriers.
- Product-liability exposure.
What generic-entry risks exist for extended phenytoin sodium?
Generic entry is legally straightforward compared with newer products, but commercial entry has several risks.
Narrow-therapeutic-index substitution
Phenytoin has a narrow therapeutic index and nonlinear pharmacokinetics. Small changes in dose or exposure can produce clinically important changes in serum concentration. The FDA has recognized the need for careful bioequivalence assessment for narrow-therapeutic-index drugs.[2]
A manufacturer must control:
- Dissolution behavior.
- Release characteristics.
- Capsule fill uniformity.
- Assay and impurity levels.
- Batch-to-batch exposure.
- Stability across shelf life.
Clinical switching risk
Patients stabilized on one formulation may require monitoring after a product change. Differences between phenytoin sodium and phenytoin free acid are also clinically relevant because the salt and free-acid forms are not interchangeable on a simple milligram-for-milligram basis.
Inventory risk
Low-margin products are vulnerable to discontinuation. A manufacturer may reduce production when price erosion exceeds the value of maintaining the product line. That can create short-term shortages even when long-term demand remains intact.
What formulation patents protect extended phenytoin sodium?
The original commercial value came from an extended-release capsule that releases phenytoin over time and supports less frequent dosing than immediate-release products. The formulation itself is mature and does not provide a durable modern patent moat.
The commercial formulation value lies in execution:
- Consistent extended-release performance.
- Acceptable dissolution profiles.
- Dose uniformity.
- Shelf stability.
- Patient adherence.
- Compatibility with therapeutic drug monitoring.
A new formulation could potentially create differentiated intellectual property if it improved exposure consistency, reduced monitoring, or enabled a better delivery profile. Such a product would need to demonstrate clinical and commercial value against inexpensive generic capsules.
How does extended phenytoin sodium compare with competing antiseizure drugs?
| Product |
Market status |
Main competitive advantage |
Main limitation |
| Extended phenytoin sodium |
Mature generic |
Low cost and established use |
Drug interactions, monitoring, nonlinear kinetics |
| Levetiracetam |
Generic and branded history |
Simple dosing and fewer interactions |
Behavioral adverse effects in some patients |
| Lamotrigine |
Generic and branded history |
Broad use and established efficacy |
Slow titration and serious rash risk |
| Valproate |
Generic |
Broad-spectrum efficacy |
Reproductive and metabolic safety concerns |
| Fosphenytoin |
Branded/generic injectable |
Parenteral prodrug for acute use |
Hospital-focused and higher cost |
| Carbamazepine |
Generic |
Established efficacy |
Interactions and tolerability concerns |
The main substitution risk is clinical migration to drugs with simpler pharmacokinetics and fewer interactions. The main retention factors are low cost, physician familiarity, and the stability of patients who have used phenytoin successfully for years.
What FDA regulatory status applies to extended phenytoin sodium?
Extended phenytoin sodium capsules are approved prescription drug products under the FDA’s small-molecule framework. Generic products are approved through abbreviated new drug applications, which require pharmaceutical equivalence and bioequivalence to the reference listed drug.[1]
The regulatory obligations remain meaningful because:
- Phenytoin is a narrow-therapeutic-index medicine.
- Product performance must remain consistent across batches.
- Manufacturing deviations can affect clinical exposure.
- Labeling must distinguish dosage forms and salt forms.
- FDA postmarket surveillance can identify quality or substitution issues.
There is no biosimilar pathway for extended phenytoin sodium. It is a chemically synthesized small molecule, so biosimilar risk is not applicable.
What patent litigation and settlement agreements affect the market?
No active, high-value patent litigation or settlement structure is central to the current U.S. market for extended phenytoin sodium. The relevant litigation cycle occurred during the transition from branded exclusivity to generic competition.
Any current dispute is more likely to involve:
- Product liability.
- Manufacturing quality.
- Supply contracts.
- Trademark use.
- False advertising.
- Distribution or pricing conduct.
These issues differ from Paragraph IV patent litigation and generally do not create a durable market-exclusion period.
What licensing deals affect extended phenytoin sodium?
The product has no widely disclosed current licensing transaction that materially changes market economics. Historic commercialization arrangements helped distribute the Dilantin franchise, but the modern generic market is shaped more by ANDA ownership, manufacturing transfers, and supply agreements than by high-value licensing.
A meaningful transaction would likely involve:
- Acquisition of an ANDA portfolio.
- Transfer of manufacturing rights.
- API supply arrangements.
- Hospital or government procurement contracts.
- Regional commercialization rights.
Because product-level revenue is usually not disclosed, licensing economics are difficult to isolate from broader mature-product portfolios.
What geographic markets are most relevant?
The United States is commercially important because of its large generic-prescription market and detailed FDA substitution framework. Europe, Japan, Canada, and emerging markets also use phenytoin, but product availability, formulation, reimbursement, and substitution rules differ.
Geographic considerations include:
| Region |
Market dynamic |
| United States |
Generic price competition and payer-driven substitution |
| European Union |
Country-level reimbursement and procurement variation |
| Japan |
Local regulatory and prescribing conventions |
| Emerging markets |
Greater reliance on low price and local distribution |
| Hospital-heavy markets |
Supply reliability and tender performance are decisive |
International revenue can remain viable where generic competition is less intense, but regulatory registrations and local distribution costs reduce the value of small markets.
What generic launch scenarios are likely?
Base case
The market remains supplied by several generic manufacturers. Prices stay low, prescription volume gradually declines, and revenue remains stable to modestly negative.
Upside case
A competitor exits or experiences a manufacturing interruption. Remaining suppliers gain temporary share and may improve net pricing.
Downside case
Clinical substitution accelerates, more manufacturers discontinue the product, and reimbursement pressure reduces market value faster than supply concentration can support pricing.
The most likely outcome is a low-growth, low-investment market with episodic supply-driven price movements.
Key Takeaways
- Extended phenytoin sodium is a mature, largely genericized antiseizure product.
- Dilantin Kapseals is the reference extended-release capsule, but generic products supply most market volume.
- Core patent and regulatory exclusivity have expired; no meaningful modern patent moat remains.
- Standalone product revenue is not publicly disclosed by major manufacturers.
- Financial performance depends on volume retention, manufacturing cost, reimbursement, and supply reliability.
- The main competitive threat is substitution by newer antiseizure medicines, not Paragraph IV patent litigation.
- Narrow-therapeutic-index requirements make quality, dissolution, and switching management important.
- Biosimilar risk does not apply.
- The most plausible commercial trajectory is flat to declining revenue with periodic supply-related pricing volatility.
FAQs
Is extended phenytoin sodium still profitable for generic manufacturers?
It can remain profitable at efficient manufacturing scale, but margins are constrained by low prices, payer pressure, quality costs, and limited market growth.
Is Dilantin Kapseals still patent protected?
The core product protections are long expired. The brand may retain trademark value, but trademarks do not prevent approved generic competition.
Can patients switch between extended phenytoin sodium manufacturers?
Switching may be clinically possible, but phenytoin’s narrow therapeutic index and nonlinear pharmacokinetics support monitoring when the manufacturer or dosage form changes.
Is fosphenytoin a direct commercial substitute for extended phenytoin sodium?
No. Fosphenytoin is an injectable prodrug used mainly in acute or inpatient settings, while extended phenytoin sodium capsules are oral maintenance therapy.
Will extended phenytoin sodium face biosimilar competition?
No. Phenytoin sodium is a chemically synthesized small molecule regulated through generic drug pathways, not biologic biosimilar pathways.
References
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
-
U.S. Food and Drug Administration. (2018). Phenytoin sodium: Product-specific guidance for industry. FDA. https://www.fda.gov
-
DailyMed. (n.d.). Dilantin Kapseals: Phenytoin sodium extended-release capsules prescribing information. National Library of Medicine. https://dailymed.nlm.nih.gov
-
National Library of Medicine. (n.d.). Phenytoin. MedlinePlus. https://medlineplus.gov/druginfo/meds/a682022.html
-
U.S. Food and Drug Administration. (2017). Approved drug products with therapeutic equivalence evaluations: Generic drug standards and therapeutic equivalence. FDA. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/therapeutic-equivalence-evaluations
